Oxidative stress: The achilles' heel of neurodegenerative diseases of the retina

Frontiers in Bioscience

Volumn 17, Issue 5, 2012, Pages 1976-1995

  Cai, Xue ^a   McGinnis, James F ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Age related macular degeneration; Animal models; Mechanism; Nanoceria; Neovascularization; Reactive oxygen species; Review; Risk factors; Therapies

Indexed keywords

ANIMALIA;

ANIMAL; DISEASE MODEL; HUMAN; METABOLISM; MOUSE; OXIDATIVE STRESS; RETINA MACULA DEGENERATION; REVIEW; RISK FACTOR;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MACULAR DEGENERATION; MICE; OXIDATIVE STRESS; RISK FACTORS;

EID: 84858593367     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4033     Document Type: Review

References (161)

1. A. C. Bird: Age-related macular disease. Br J Ophthalmol 80, 2-3 (1996).
2. A. C. Bird: Therapeutic targets in age-related macular disease. J Clin Invest 120, 3033-41 (2010).
3. P. Elizabeth Rakoczy, M. J. Yu, S. Nusinowitz, B. Chang, J. R. Heckenlively: Mouse models of age-related macular degeneration. Exp Eye Res 82, 741-52 (2006). (Pubitemid 43170875)
4. A. O. Edwards, G. Malek: Molecular genetics of AMD and current animal models. Angiogenesis 10, 119-32 (2007). (Pubitemid 46440627)
5. G. Malek, L. V. Johnson, B. E. Mace, P. Saloupis, D. E. Schmechel, D. W. Rickman, C. A. Toth, P. M. Sullivan, C. Bowes Rickman: Apolipoprotein E allele-dependent pathogenesis: a model for age-related retinal degeneration. Proc Natl Acad Sci USA 102, 11900-5 (2005). (Pubitemid 41170822)
6. H. R. Coleman, C. C. Chan, F. L. Ferris, 3rd, E. Y. Chew: Age-related macular degeneration. Lancet 372, 1835-45 (2008).
7. D. Zhu, X. Deng, J. Xu, D. R. Hinton: What determines the switch between atrophic and neovascular forms of age related macular degeneration? - the role of BMP4 induced senescence. Aging (Albany NY) 1, 740-5 (2009).
8. J. Xu, D. Zhu, S. He, C. Spee, S. J. Ryan, D. R. Hinton: Transcriptional regulation of bone morphogenetic protein 4 by tumor necrosis factor and its relationship with age-related macular degeneration. FASEB J 25, 2221-33 (2011).
9. X. Yuan, X. Gu, J. S. Crabb, X. Yue, K. Shadrach, J. G. Hollyfield, J. W. Crabb: Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes. Mol Cell Proteomics 9, 1031-46 (2010).
10. R. Liutkeviciene, V. Lesauskaite, V. Asmoniene, D. Zaliuniene, V. Jasinskas: Factors determining agerelated macular degeneration: a current view. Medicina (Kaunas) 46, 89-94 (2010).
11. B. S. Winkler, M. E. Boulton, J. D. Gottsch, P. Sternberg: Oxidative damage and age-related macular degeneration. Mol Vis 5, 32 (1999).
12. J. Liu, Y. Itagaki, S. Ben-Shabat, K. Nakanishi, J. R. Sparrow: The biosynthesis of A2E, a fluorophore of aging retina, involves the formation of the precursor, A2-PE, in the photoreceptor outer segment membrane. J Biol Chem 275, 29354-60 (2000). (Pubitemid 32043807)
13. D. H. Anderson, R. F. Mullins, G. S. Hageman, L. V. Johnson: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134, 411-31 (2002).
14. B. Zanke, S. Hawken, R. Carter, D. Chow: A genetic approach to stratification of risk for age-related macular degeneration. Can J Ophthalmol 45, 22-7 (2010).
15. S. Sivaprasad, N. V. Chong: The complement system and age-related macular degeneration. Eye (Lond) 20, 867- 72 (2006). (Pubitemid 44210177)
16. G. S. Hageman, D. H. Anderson, L. V. Johnson, L. S. Hancox, A. J. Taiber, L. I. Hardisty, J. L. Hageman, H. A. Stockman, J. D. Borchardt, K. M. Gehrs, R. J. Smith, G. Silvestri, S. R. Russell, C. C. Klaver, I. Barbazetto, S. Chang, L. A. Yannuzzi, G. R. Barile, J. C. Merriam, R. T. Smith, A. K. Olsh, J. Bergeron, J. Zernant, J. E. Merriam, B. Gold, M. Dean, R. Allikmets: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102, 7227-32 (2005). (Pubitemid 40696361)
17. R. J. Klein, C. Zeiss, E. Y. Chew, J. Y. Tsai, R. S. Sackler, C. Haynes, A. K. Henning, J. P. SanGiovanni, S. M. Mane, S. T. Mayne, M. B. Bracken, F. L. Ferris, J. Ott, C. Barnstable, J. Hoh: Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-9 (2005). (Pubitemid 40530070)
18. Z. Wu, T. W. Lauer, A. Sick, S. F. Hackett, P. A. Campochiaro: Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem 282, 22414-25 (2007). (Pubitemid 47267308)
19. V. V. Lyzogubov, R. G. Tytarenko, P. Jha, J. Liu, N. S. Bora, P. S. Bora: Role of ocular complement factor H in a murine model of choroidal neovascularization. Am J Pathol 177, 1870-80 (2010).
20. J. Maller, S. George, S. Purcell, J. Fagerness, D. Altshuler, M. J. Daly, J. M. Seddon: Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 38, 1055-9 (2006). (Pubitemid 44325932)
21. E. Gorgun, M. Guven, M. Unal, B. Batar, G. S. Guven, M. Yenerel, S. Tatlipinar, M. Seven, A. Yuksel: Polymorphisms of the DNA repair genes XPD and XRCC1 and the risk of age-related macular degeneration. Invest Ophthalmol Vis Sci 51, 4732-7 (2010).
22. M. Kowalski, A. Bielecka-Kowalska, K. Oszajca, E. Makandjou-Ola, P. Jaworski, J. Bartkowiak, J. Szemraj: Manganese superoxide dismutase (MnSOD) gene (Ala- 9Val, Ile58Thr) polymorphism in patients with age-related macular degeneration (AMD). Med Sci Monit 16, 190- 196 (2010).
23. F. Bonomini, F. Filippini, T. Hayek, M. Aviram, S. Keidar, L. F. Rodella, R. Coleman, R. Rezzani: Apolipoprotein E and its role in aging and survival. Exp Gerontol 45, 149-57 (2010).
24. S. Beatty, H. Koh, M. Phil, D. Henson, M. Boulton: The role of oxidative stress in the pathogenesis of agerelated macular degeneration. Surv Ophthalmol 45, 115-34 (2000).
25. B. Halliwell: Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 91, 14S-22S (1991).
26. N. N. Osborne, T. A. Kamalden, A. S. Majid, S. del Olmo-Aguado, A. G. Manso, D. Ji: Light effects on mitochondrial photosensitizers in relation to retinal degeneration. Neurochem Res 35, 2027-34 (2010).
27. R. W. Young, D. Bok: Participation of the retinal pigment epithelium in the rod outer segment renewal process. J Cell Biol 42, 392-403 (1969).
28. B. Rohrer, Q. Long, B. Coughlin, B. Renner, Y. Huang, K. Kunchithapautham, V. P. Ferreira, M. K. Pangburn, G. S. Gilkeson, J. M. Thurman, S. Tomlinson, V. M. Holers: A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of agerelated macular degeneration. Adv Exp Med Biol 703, 137- 49 (2010).
29. Y. Totan, R. Yagci, Y. Bardak, H. Ozyurt, F. Kendir, G. Yilmaz, S. Sahin, U. Sahin Tig: Oxidative macromolecular damage in age-related macular degeneration. Curr Eye Res 34, 1089-93 (2009).
30. L. I. Lau, C. J. Liu, Y. H. Wei: Increase of 8-hydroxy- 2'-deoxyguanosine in aqueous humor of patients with exudative age-related macular degeneration. Invest Ophthalmol Vis Sci 51, 5486-90 (2010).
31. J. W. Crabb, M. Miyagi, X. Gu, K. Shadrach, K. A. West, H. Sakaguchi, M. Kamei, A. Hasan, L. Yan, M. E. Rayborn, R. G. Salomon, J. G. Hollyfield: Drusen proteome analysis: an approach to the etiology of agerelated macular degeneration. Proc Natl Acad Sci USA 99, 14682-7 (2002). (Pubitemid 35334544)
32. A. Decanini, C. L. Nordgaard, X. Feng, D. A. Ferrington, T. W. Olsen: Changes in select redox proteins of the retinal pigment epithelium in age-related macular degeneration. Am J Ophthalmol 143, 607-15 (2007).
33. M. Suzuki, M. Kamei, H. Itabe, K. Yoneda, H. Bando, N. Kume, Y. Tano: Oxidized phospholipids in the macula increase with age and in eyes with age-related macular degeneration. Mol Vis 13, 772-8 (2007). (Pubitemid 46850583)
34. S. J. Fliesler, R. E. Anderson: Chemistry and metabolism of lipids in the vertebrate retina. Prog Lipid Res 22, 79-131 (1983).
35. R. E. Anderson, P. M. Lissandrello, M. B. Maude, M. T. Matthes: Lipids of bovine retinal pigment epithelium. Exp Eye Res 23, 149-57 (1976).
36. J. G. Hollyfield: Age-related macular degeneration: the molecular link between oxidative damage, tissue-specific inflammation and outer retinal disease: the Proctor lecture. Invest Ophthalmol Vis Sci 51, 1275-81 (2010).
37. J. G. Hollyfield, R. G. Salomon, J. W. Crabb: Proteomic approaches to understanding age-related macular degeneration. Adv Exp Med Biol 533, 83-9 (2003). (Pubitemid 38005267)
38. J. G. Hollyfield, V. L. Perez, R. G. Salomon: A hapten generated from an oxidation fragment of docosahexaenoic acid is sufficient to initiate age-related macular degeneration. Mol Neurobiol 41, 290-8 (2010).
39. J. R. Dias, E. B. Rodrigues, M. Maia, O. Magalhaes, Jr., F. M. Penha, M. E. Farah: Cytokines in neovascular agerelated macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol (2011).
40. C. N. Nagineni, V. K. Kommineni, A. William, B. Detrick, J. J. Hooks: Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol (2011).
41. R. A. Radu, J. Hu, Q. Yuan, D. L. Welch, J. Makshanoff, M. Lloyd, S. McMullen, G. H. Travis, D. Bok: Complement system dysregulation and inflammation in the retinal pigment epithelium of a mouse model for stargardt macular degeneration. J Biol Chem 286, 18593- 601 (2011).
42. A. Salminen, A. Kauppinen, J. M. Hyttinen, E. Toropainen, K. Kaarniranta: Endoplasmic reticulum stress in age-related macular degeneration: trigger for neovascularization. Mol Med 16, 535-42 (2010).
43. M. Shimazawa, Y. Inokuchi, Y. Ito, H. Murata, M. Aihara, M. Miura, M. Araie, H. Hara: Involvement of ER stress in retinal cell death. Mol Vis 13, 578-87 (2007). (Pubitemid 46561917)
44. T. Sauer, M. Patel, C. C. Chan, J. Tuo: Unfolding the therapeutic potential of chemical chaperones for age-related macular degeneration. Expert Rev Ophthalmol 3, 29-42 (2008). (Pubitemid 351993044)
45. C. M. Ethen, C. Reilly, X. Feng, T. W. Olsen, D. A. Ferrington: The proteome of central and peripheral retina with progression of age-related macular degeneration. Invest Ophthalmol Vis Sci 47, 2280-90 (2006). (Pubitemid 351639806)
46. C. C. Chan, R. J. Ross, D. Shen, X. Ding, Z. Majumdar, C. M. Bojanowski, M. Zhou, N. Salem, Jr., R. Bonner, J. Tuo: Ccl2/Cx3cr1-deficient mice: an animal model for agerelated macular degeneration. Ophthalmic Res 40, 124-8 (2008). (Pubitemid 351562889)
47. Y. Cho, X. Cao, D. Shen, J. Tuo, L. M. Parver, F. R. Rickles, C. C. Chan: Evidence for enhanced tissue factor expression in age-related macular degeneration. Lab Invest 91, 519-26 (2011).
48. A. A. Herzlich, J. Tuo, C. C. Chan: Peroxisome proliferator-activated receptor and age-related macular degeneration. PPAR Res 2008, 389507 (2008).
49. A. A. Herzlich, X. Ding, D. Shen, R. J. Ross, J. Tuo, C. C. Chan: Peroxisome Proliferator-Activated Receptor Expression in Murine Models and Humans with Agerelated Macular Degeneration. Open Biol J 2, 141-148 (2009).
50. W. C. Wu, D. N. Hu, H. X. Gao, M. Chen, D. Wang, R. Rosen, S. A. McCormick: Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by retinal pigment epithelial cells. Mol Vis 16, 1864-73 (2010).
51. V. Justilien, J. J. Pang, K. Renganathan, X. Zhan, J. W. Crabb, S. R. Kim, J. R. Sparrow, W. W. Hauswirth, A. S. Lewin: SOD2 knockdown mouse model of early AMD. Invest Ophthalmol Vis Sci 48, 4407-20 (2007). (Pubitemid 351260953)
52. N. B. Javitt, J. C. Javitt: The retinal oxysterol pathway: a unifying hypothesis for the cause of age-related macular degeneration. Curr Opin Ophthalmol 20, 151-7 (2009).
53. B. Dasari, J. R. Prasanthi, G. Marwarha, B. B. Singh, O. Ghribi: The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol 10, 22 (2010).
54. K. S. Plafker, L. Nguyen, M. Barneche, S. Mirza, D. Crawford, S. M. Plafker: The ubiquitin-conjugating enzyme UbcM2 can regulate the stability and activity of the antioxidant transcription factor Nrf2. J Biol Chem 285, 23064-74 (2010).
55. S. M. Plafker: Oxidative stress and the ubiquitin proteolytic system in age-related macular degeneration. Adv Exp Med Biol 664, 447-56 (2010).
56. B. Medicherla, A. L. Goldberg: Heat shock and oxygen radicals stimulate ubiquitin-dependent degradation mainly of newly synthesized proteins. J Cell Biol 182, 663-73 (2008).
57. S. H. Byeon, S. C. Lee, S. H. Choi, H. K. Lee, J. H. Lee, Y. K. Chu, O. W. Kwon: Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGFR2/PI3K/Akt. Invest Ophthalmol Vis Sci 51, 1190-7 (2010).
58. C. N. Roybal, L. Y. Marmorstein, D. L. Vander Jagt, S. F. Abcouwer: Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression. Invest Ophthalmol Vis Sci 46, 3973-9 (2005). (Pubitemid 44264595)
59. J. C. Khan, D. A. Thurlby, H. Shahid, D. G. Clayton, J. R. Yates, M. Bradley, A. T. Moore, A. C. Bird: Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90, 75-80 (2006). (Pubitemid 43029901)
60. M. Cano, R. Thimmalappula, M. Fujihara, N. Nagai, M. Sporn, A. L. Wang, A. H. Neufeld, S. Biswal, J. T. Handa: Cigarette smoking, oxidative stress, the anti-oxidant response through Nrf2 signaling, and Age-related Macular Degeneration. Vision Res 50, 652-64 (2010).
61. K. M. Bertram, C. J. Baglole, R. P. Phipps, R. T. Libby: Molecular regulation of cigarette smoke induced-oxidative stress in human retinal pigment epithelial cells: implications for agerelated macular degeneration. Am J Physiol Cell Physiol 297, 1200-10 (2009).
62. M. Fujihara, N. Nagai, T. E. Sussan, S. Biswal, J. T. Handa: Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS One 3, e3119 (2008).
63. M. Pons, M. E. Marin-Castano: Cigarette Smoke-Related Hydroquinone Dysregulates MCP-1, VEGF and PEDF Expression in Retinal Pigment Epithelium in vitro and in vivo. PLoS One 6, e16722 (2011).
64. M. Pons, S. W. Cousins, K. G. Csaky, G. Striker, M. E. Marin- Castano: Cigarette smoke-related hydroquinone induces filamentous actin reorganization and heat shock protein 27 phosphorylation through p38 and extracellular signal-regulated kinase 1/2 in retinal pigment epithelium: implications for agerelated macular degeneration. Am J Pathol 177, 1198-213 (2010).
65. J. Blasiak, A. Sklodowska, M. Ulinska, J. P. Szaflik: Iron and age-related macular degeneration. Klin Oczna 111, 174-7 (2009).
66. M. Hadziahmetovic, T. Dentchev, Y. Song, N. Haddad, X. He, P. Hahn, D. Pratico, R. Wen, Z. L. Harris, J. D. Lambris, J. Beard, J. L. Dunaief: Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci 49, 2728-36 (2008).
67. V. V. Lyzogubov, R. G. Tytarenko, J. Liu, N. S. Bora, P. S. Bora: Polyethylene Glycol (PEG)-induced Mouse Model of Choroidal Neovascularization. J Biol Chem 286, 16229-37 (2011).
68. H. L. Ramkumar, J. Zhang, C. C. Chan: Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD). Prog Retin Eye Res 29, 169-90 (2010).
69. L. L. Molday, A. R. Rabin, R. S. Molday: ABCR expression in foveal cone photoreceptors and its role in Stargardt macular dystrophy. Nat Genet 25, 257-8 (2000). (Pubitemid 30437308)
70. H. Sun, J. Nathans: Stargardt's ABCR is localized to the disc membrane of retinal rod outer segments. Nat Genet 17, 15-6 (1997).
71. J. Weng, N. L. Mata, S. M. Azarian, R. T. Tzekov, D. G. Birch, G. H. Travis: Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 98, 13-23 (1999). (Pubitemid 29331192)
72. N. L. Mata, J. Weng, G. H. Travis: Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc Natl Acad Sci USA 97, 7154-9 (2000). (Pubitemid 30431433)
73. H. Sun, R. S. Molday, J. Nathans: Retinal stimulates ATP hydrolysis by purified and reconstituted ABCR, the photoreceptor-specific ATP-binding cassette transporter responsible for Stargardt disease. J Biol Chem 274, 8269- 81 (1999).
74. R. Allikmets, N. Singh, H. Sun, N. F. Shroyer, A. Hutchinson, A. Chidambaram, B. Gerrard, L. Baird, D. Stauffer, A. Peiffer, A. Rattner, P. Smallwood, Y. Li, K. L. Anderson, R. A. Lewis, J. Nathans, M. Leppert, M. Dean, J. R. Lupski: A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 15, 236-46 (1997). (Pubitemid 27098715)
75. K. Jaakson, J. Zernant, M. Kulm, A. Hutchinson, N. Tonisson, D. Glavac, M. Ravnik-Glavac, M. Hawlina, M. R. Meltzer, R. C. Caruso, F. Testa, A. Maugeri, C. B. Hoyng, P. Gouras, F. Simonelli, R. A. Lewis, J. R. Lupski, F. P. Cremers, R. Allikmets: Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat 22, 395- 403 (2003). (Pubitemid 37346112)
76. N. L. Mata, R. T. Tzekov, X. Liu, J. Weng, D. G. Birch, G. H. Travis: Delayed dark-adaptation and lipofuscin accumulation in abcr+/- mice: implications for involvement of ABCR in age-related macular degeneration. Invest Ophthalmol Vis Sci 42, 1685-90 (2001). (Pubitemid 32652338)
77. L. Wu, T. Nagasaki, J. R. Sparrow: Photoreceptor cell degeneration in abcr (-/-) mice. Adv Exp Med Biol 664, 533-9 (2010).
78. M. P. Agbaga, R. S. Brush, M. N. Mandal, K. Henry, M. H. Elliott, R. E. Anderson: Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proc Natl Acad Sci USA 105, 12843-8 (2008).
79. P. Tvrdik, R. Westerberg, S. Silve, A. Asadi, A. Jakobsson, B. Cannon, G. Loison, A. Jacobsson: Role of a new mammalian gene family in the biosynthesis of very long chain fatty acids and sphingolipids. J Cell Biol 149, 707-18 (2000).
80. M. P. Agbaga, M. N. Mandal, R. E. Anderson: Retinal very long-chain PUFAs: new insights from studies on ELOVL4 protein. J Lipid Res 51, 1624-42 (2010).
81. G. Karan, Z. Yang, K. Howes, Y. Zhao, Y. Chen, D. J. Cameron, Y. Lin, E. Pearson, K. Zhang: Loss of ER retention and sequestration of the wild-type ELOVL4 by Stargardt disease dominant negative mutants. Mol Vis 11, 657-64 (2005). (Pubitemid 41410208)
82. K. Zhang, M. Kniazeva, M. Han, W. Li, Z. Yu, Z. Yang, Y. Li, M. L. Metzker, R. Allikmets, D. J. Zack, L. E. Kakuk, P. S. Lagali, P. W. Wong, I. M. MacDonald, P. A. Sieving, D. J. Figueroa, C. P. Austin, R. J. Gould, R. Ayyagari, K. Petrukhin: A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet 27, 89-93 (2001). (Pubitemid 32044525)
83. G. Karan, C. Lillo, Z. Yang, D. J. Cameron, K. G. Locke, Y. Zhao, S. Thirumalaichary, C. Li, D. G. Birch, H. R. Vollmer-Snarr, D. S. Williams, K. Zhang: Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor degeneration in mutant ELOVL4 transgenic mice: a model for macular degeneration. Proc Natl Acad Sci USA 102, 4164-9 (2005). (Pubitemid 40388573)
84. H. E. Grossniklaus, S. J. Kang, L. Berglin: Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 29, 500-19 (2010).
85. T. Tobe, S. Ortega, J. D. Luna, H. Ozaki, N. Okamoto, N. L. Derevjanik, S. A. Vinores, C. Basilico, P. A. Campochiaro: Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol 153, 1641-6 (1998). (Pubitemid 28509922)
86. J. R. Heckenlively, N. L. Hawes, M. Friedlander, S. Nusinowitz, R. Hurd, M. Davisson, B. Chang: Mouse model of subretinal neovascularization with choroidal anastomosis. Retina 23, 518-22 (2003). (Pubitemid 37071966)
87. W. Hu, A. Jiang, J. Liang, H. Meng, B. Chang, H. Gao, X. Qiao: Expression of VLDLR in the retina and evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous proliferation. Invest Ophthalmol Vis Sci 49, 407-15 (2008).
88. P. K. Frykman, M. S. Brown, T. Yamamoto, J. L. Goldstein, J. Herz: Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci USA 92, 8453-7 (1995).
89. Y. Chen, Y. Hu, G. Moiseyev, K. K. Zhou, D. Chen, J. X. Ma: Photoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiency. Microvasc Res 78, 119-27 (2009).
90. M. I. Dorrell, E. Aguilar, R. Jacobson, O. Yanes, R. Gariano, J. Heckenlively, E. Banin, G. A. Ramirez, M. Gasmi, A. Bird, G. Siuzdak, M. Friedlander: Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest 119, 611-623 (2009).
91. C. Li, Z. Huang, R. Kingsley, X. Zhou, F. Li, D. W. Parke ,2nd, W. Cao: Biochemical alterations in the retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal angiomatous proliferation. Arch Ophthalmol 125, 795-803 (2007). (Pubitemid 46919741)
92. Y. Chen, Y. Hu, K. Lu, J. G. Flannery, J. X. Ma: Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J Biol Chem 282, 34420-8 (2007). (Pubitemid 350159486)
93. A. Dong, B. Xie, J. Shen, T. Yoshida, K. Yokoi, S. F. Hackett, P. A. Campochiaro: Oxidative stress promotes ocular neovascularization. J Cell Physiol 219, 544-52 (2009).
94. Y. Imamura, S. Noda, K. Hashizume, K. Shinoda, M. Yamaguchi, S. Uchiyama, T. Shimizu, Y. Mizushima, T. Shirasawa, K. Tsubota: Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. Proc Natl Acad Sci USA 103, 11282-7 (2006). (Pubitemid 44156510)
95. K. Hashizume, M. Hirasawa, Y. Imamura, S. Noda, T. Shimizu, K. Shinoda, T. Kurihara, K. Noda, Y. Ozawa, S. Ishida, Y. Miyake, T. Shirasawa, K. Tsubota: Retinal dysfunction and progressive retinal cell death in SOD1-deficient mice. Am J Pathol 172, 1325-31 (2008). (Pubitemid 351671545)
96. T. W. Mittag, A. U. Bayer, Vail Mm La: Lightinduced retinal damage in mice carrying a mutated SOD I gene. Exp Eye Res 69, 677-83 (1999). (Pubitemid 30046893)
97. N. S. Bhise, R. B. Shmueli, J. C. Sunshine, S. Y. Tzeng, J. J. Green: Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opin Drug Deliv 8, 485-504 (2011).
98. C. Campa, S. P. Harding: Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12, 173-81 (2011).
99. F. Enseleit, S. Michels, F. Ruschitzka: Anti- VEGF therapies and blood pressure: more than meets the eye. Curr Hypertens Rep 12, 33-8 (2010).
100. M. Friedlander: Combination angiostatic therapies: targeting multiple angiogenic pathways. Retina 29, S27-9 (2009).
101. U. Chakravarthy, J. Evans, P. J. Rosenfeld: Age related macular degeneration. BMJ 340, c981 (2010).
102. M. Caputo, H. Zirpoli, R. Di Benedetto, K. De Nadai, M. F. Tecce: Perspectives of choroidal neovascularization therapy. Curr Drug Targets 12, 234-42 (2011).
103. R. Hara, Y. Inomata, T. Kawaji, N. Sagara, M. Inatani, M. Fukushima, H. Tanihara: Suppression of choroidal neovascularization by N-acetyl-cysteine in mice. Curr Eye Res 35, 1012-20 (2010).
104. L. Zhao, B. V. Sweet: Lutein and zeaxanthin for macular degeneration. Am J Health Syst Pharm 65, 1232-8 (2008). (Pubitemid 351898356)
105. A. J. Chucair, N. P. Rotstein, J. P. Sangiovanni, A. During, E. Y. Chew, L. E. Politi: Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid. Invest Ophthalmol Vis Sci 48, 5168-77 (2007). (Pubitemid 351260928)
106. A. S. Prasad: Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr 28, 257-65 (2009).
107. K. Kaarniranta, A. Salminen: NF-kappaB signaling as a putative target for omega-3 metabolites in the prevention of age-related macular degeneration (AMD). Exp Gerontol 44, 685-8 (2009).
108. J. Tuo, R. J. Ross, A. A. Herzlich, D. Shen, X. Ding, M. Zhou, S. L. Coon, N. Hussein, N. Salem, Jr., C. C. Chan: A high omega-3 fatty acid diet reduces retinal lesions in a murine model of macular degeneration. Am J Pathol 175, 799-807 (2009).
109. Z. Feng, Z. Liu, X. Li, H. Jia, L. Sun, C. Tian, L. Jia, J. Liu: alpha-Tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. J Nutr Biochem 21, 1222-31 (2010).
110. R. Rastmanesh: Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. Med Hypotheses 76, 79- 85 (2011).
111. R. A. Radu, N. L. Mata, S. Nusinowitz, X. Liu, P. A. Sieving, G. H. Travis: Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci USA 100, 4742-7 (2003). (Pubitemid 36457800)
112. R. A. Radu, Q. Yuan, J. Hu, J. H. Peng, M. Lloyd, S. Nusinowitz, D. Bok, G. H. Travis: Accelerated accumulation of lipofuscin pigments in the RPE of a mouse model for ABCA4-mediated retinal dystrophies following Vitamin A supplementation. Invest Ophthalmol Vis Sci 49, 3821-9 (2008).
113. A. Afzal, S. Caballero, S. S. Palii, S. Jurczyk, M. Pardue, D. Geroski, H. Edelhauser, G. Hochhaus, M. Kim, A. Franklin, G. Shapiro, M. B. Grant: Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Res Bull 81, 320-6 (2010).
114. O. Benny, K. Nakai, T. Yoshimura, L. Bazinet, J. D. Akula, S. Nakao, A. Hafezi-Moghadam, D. Panigrahy, P. Pakneshan, R. J. D'Amato: Broad spectrum antiangiogenic treatment for ocular neovascular diseases. PLoS One 5, e12515 (2010).
115. T. S. Griffith, T. Brunner, S. M. Fletcher, D. R. Green, T. A. Ferguson: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-92 (1995).
116. J. Roychoudhury, J. M. Herndon, J. Yin, R. S. Apte, T. A. Ferguson: Targeting immune privilege to prevent pathogenic neovascularization. Invest Ophthalmol Vis Sci 51, 3560-6 (2010).
117. M. A. Economou, J. Wu, D. Vasilcanu, L. Rosengren, C. All-Ericsson, I. van der Ploeg, E. Menu, L. Girnita, M. Axelson, O. Larsson, S. Seregard, A. Kvanta: Inhibition of VEGF secretion and experimental choroidal neovascularization by picropodophyllin (PPP), an inhibitor of the insulin-like growth factor-1 receptor. Invest Ophthalmol Vis Sci 49, 2620-6 (2008).
118. Z. L. Chi, T. Yoshida, J. D. Lambris, T. Iwata: Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol 703, 127-35 (2010).
119. I. Ahmad, S. Balasubramanian, C. B. Del Debbio, S. Parameswaran, A. R. Katz, C. Toris, R. N. Fariss: Regulation of ocular angiogenesis by notch signaling: implications in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 52, 2868-78 (2011).
120. M. Zheng, Z. Zhang, X. Zhao, Y. Ding, H. Han: The Notch signaling pathway in retinal dysplasia and retina vascular homeostasis. J Genet Genomics 37, 573- 82 (2010).
121. T. Gridley: Notch signaling in the vasculature. Curr Top Dev Biol 92, 277-309 (2010).
122. A. K. Olsson, A. Dimberg, J. Kreuger, L. Claesson- Welsh: VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7, 359-71 (2006).
123. H. Takahashi, H. Ishizaki, H. Tahara, Y. Tamaki, Y. Yanagi: Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model. Invest Ophthalmol Vis Sci 49, 2143-7 (2008).
124. H. Takahashi, R. Obata, Y. Tamaki: A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. J Ocul Pharmacol Ther 22, 213-8 (2006). (Pubitemid 44689659)
125. H. Takahashi, Y. Tamaki, N. Ishii, N. Oikawa, E. Mizuguchi, J. H. Francis, Y. Inoue, A. Iriyama, R. Obata, Y. Yanagi: Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res 33, 1002-10 (2008).
126. L. Lu, B. C. Oveson, Y. J. Jo, T. W. Lauer, S. Usui, K. Komeima, B. Xie, P. A. Campochiaro: Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. Antioxid Redox Signal 11, 715-24 (2009).
127. S. M. Cashman, A. Desai, K. Ramo, R. Kumar-Singh: Expression of complement component 3 (c3) from an adenovirus leads to pathology in the murine retina. Invest Ophthalmol Vis Sci 52, 3436-45 (2011).
128. A. Davies, D. L. Simmons, G. Hale, R. A. Harrison, H. Tighe, P. J. Lachmann, H. Waldmann: CD59, an LY-6- like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med 170, 637-54 (1989). (Pubitemid 19226653)
129. N. S. Bora, P. Jha, V. V. Lyzogubov, S. Kaliappan, J. Liu, R. G. Tytarenko, D. A. Fraser, B. P. Morgan, P. S. Bora: Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice. J Biol Chem 285, 33826-33 (2010).
130. K. Ramo, S. M. Cashman, R. Kumar-Singh: Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE. Invest Ophthalmol Vis Sci 49, 4126-36 (2008).
131. A. Takeda, J. Z. Baffi, M. E. Kleinman, W. G. Cho, M. Nozaki, K. Yamada, H. Kaneko, R. J. Albuquerque, S. Dridi, K. Saito, B. J. Raisler, S. J. Budd, P. Geisen, A. Munitz, B. K. Ambati, M. G. Green, T. Ishibashi, J. D. Wright, A. A. Humbles, C. J. Gerard, Y. Ogura, Y. Pan, J. R. Smith, S. Grisanti, M. E. Hartnett, M. E. Rothenberg, J. Ambati: CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460, 225-30 (2009).
132. Y. Li, D. Huang, X. Xia, Z. Wang, L. Luo, R. Wen: CCR3 and Choroidal Neovascularization. PLoS One 6, e17106 (2011).
133. C. M. Lai, M. J. Estcourt, M. Wikstrom, R. P. Himbeck, N. L. Barnett, M. Brankov, L. B. Tee, S. A. Dunlop, M. A. Degli-Esposti, E. P. Rakoczy: rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci 50, 4279-87 (2009).
134. C. M. Lai, W. Y. Shen, M. Brankov, Y. K. Lai, N. L. Barnett, S. Y. Lee, I. Y. Yeo, R. Mathur, J. E. Ho, P. Pineda, A. Barathi, C. L. Ang, I. J. Constable, E. P. Rakoczy: Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12, 659-68 (2005). (Pubitemid 41350147)
135. J. Tuo, J. J. Pang, X. Cao, D. Shen, J. Zhang, A. Scaria, S. C. Wadsworth, P. Pechan, S. L. Boye, W. W. Hauswirth, C. C. Chan: AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) mice. Neurobiol Aging (2011).
136. Y. Huang, V. Enzmann, S. T. Ildstad: Stem cell-based therapeutic applications in retinal degenerative diseases. Stem Cell Rev 7, 434-45 (2011).
137. T. J. Rowland, D. E. Buchholz, D. O. Clegg: Pluripotent human stem cells for the treatment of retinal disease. J Cell Physiol (2011).
138. R. E. MacLaren, R. A. Pearson, A. MacNeil, R. H. Douglas, T. E. Salt, M. Akimoto, A. Swaroop, J. C. Sowden, R. R. Ali: Retinal repair by transplantation of photoreceptor precursors. Nature 444, 203-7 (2006). (Pubitemid 44722060)
139. V. Marchetti, T. U. Krohne, D. F. Friedlander, M. Friedlander: Stemming vision loss with stem cells. J Clin Invest 120, 3012-21 (2010).
140. G. A. Silva, N. M. Silva, T. M. Fortunato: Stem cell and tissue engineering therapies for ocular regeneration. Curr Stem Cell Res Ther 6, 255-72 (2011).
141. D. Zhu, X. Deng, C. Spee, S. Sonoda, C. L. Hsieh, E. Barron, M. Pera, D. R. Hinton: Polarized Secretion of PEDF from Human Embryonic Stem Cell-Derived RPE Promotes Retinal Progenitor Cell Survival. Invest Ophthalmol Vis Sci 52, 1573-85 (2011).
142. A. Otani, K. Kinder, K. Ewalt, F. J. Otero, P. Schimmel, M. Friedlander: Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 8, 1004-10 (2002). (Pubitemid 35033705)
143. J. Lecomte, K. Louis, B. Detry, S. Blacher, V. Lambert, S. Bekaert, C. Munaut, J. Paupert, P. Blaise, J. M. Foidart, J. M. Rakic, S. M. Krane, A. Noel: Bone marrow-derived mesenchymal cells and MMP13 contribute to experimental choroidal neovascularization. Cell Mol Life Sci 68, 677-86 (2011).
144. H. Y. Hou, H. L. Liang, Y. S. Wang, Z. X. Zhang, B. R. Wang, Y. Y. Shi, X. Dong, Y. Cai: A therapeutic strategy for choroidal neovascularization based
145. M. Tomita, H. Yamada, Y. Adachi, Y. Cui, E. Yamada, A. Higuchi, K. Minamino, Y. Suzuki, M. Matsumura, S. Ikehara: Choroidal neovascularization is provided by bone marrow cells. Stem Cells 22, 21- 6 (2004). (Pubitemid 38018778)
146. K. M. Farjo, J. X. Ma: The potential of nanomedicine therapies to treat neovascular disease in the retina. J Angiogenes Res 2, 21 (2010).
147. X. Cai, S. Conley, M. Naash: Nanoparticle applications in ocular gene therapy. Vision Res 48, 319-24 (2008). (Pubitemid 351179511)
148. R. Ellis-Behnke, J. B. Jonas: Redefining tissue engineering for nanomedicine in ophthalmology. Acta Ophthalmol. 89 e108-14 (2011).
149. S. Tsunekawa, R. Sahara, Y. Kawazoe, K. Ishikawa: Lattice relaxation of manosize CeO2-X nanocrystalline particles. Applied Surface Science 152, 53-56 (1999). (Pubitemid 30505783)
150. A. S. Karakoti, S. Singh, A. Kumar, M. Malinska, S. V. Kuchibhatla, K. Wozniak, W. T. Self, S. Seal: PEGylated nanoceria as radical scavenger with tunable redox chemistry. J Am Chem Soc 131, 14144-5 (2009).
151. J. Chen, S. Patil, S. Seal, J. F. McGinnis: Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nat Nanotechnol 1, 142-50 (2006).
152. A. Vincent, T. M. Inerbaev, S. Babu, A. S. Karakoti, W. T. Self, A. E. Masunov, S. Seal: Tuning hydrated nanoceria surfaces: experimental/theoretical investigations of ion exchange and implications in organic and inorganic interactions. Langmuir 26, 7188-98 (2010).
153. J. M. Perez, A. Asati, S. Nath, C. Kaittanis: Synthesis of biocompatible dextran-coated nanoceria with pHdependent antioxidant properties. Small 4, 552-6 (2008). (Pubitemid 351808047)
154. E. G. Heckert, A. S. Karakoti, S. Seal, W. T. Self: The role of cerium redox state in the SOD mimetic activity of nanoceria. Biomaterials 29, 2705-9 (2008).
155. J. Chen, S. Patil, S. Seal, J. F. McGinnis: Nanoceria particles prevent ROI-induced blindness. Adv Exp Med Biol 613, 53-9 (2008).
156. S. M. Hirst, A. S. Karakoti, R. D. Tyler, N. Sriranganathan, S. Seal, C. M. Reilly: Antiinflammatory properties of cerium oxide nanoparticles. Small 5, 2848-56 (2009).
157. N. Link, T. J. Brunner, I. A. Dreesen, W. J. Stark, M. Fussenegger: Inorganic nanoparticles for transfection of mammalian cells and removal of viruses from aqueous solutions. Biotechnol Bioeng 98, 1083-93 (2007). (Pubitemid 350205584)
158. B. K. Pierscionek, Y. Li, A. A. Yasseen, L. M. Colhoun, R. A. Schachar, W. Chen: Nanoceria have no genotoxic effect on human lens epithelial cells. Nanotechnology 21, 035102 (2010).
159. L. L. Wong, Q. N. Pye, S. M. Hirst, X. Cai, C. M. Reilly, S. Seal, J. F. McGinnis: Pharmacokinetics and effects of nanoceria in normal and P23H degenerative rat retinas. ARVO abstract #3416 (2011).
160. L. Kong, X. Cai, X. Zhou, L. L. Wong, A. S. Karakoti, S. Seal, J. F. McGinnis: Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways. Neurobiol Dis 42, 514-23 (2011).
161. X. Zhou, L. L. Wong, A. S. Karakoti, S. Seal, J. F. McGinnis: Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the vldlr knockout mouse. PLoS One 6, e16733 (2011).